Skip to main content
Acta Crystallographica Section F: Structural Biology Communications logoLink to Acta Crystallographica Section F: Structural Biology Communications
. 2014 Aug 29;70(Pt 9):1162–1166. doi: 10.1107/S2053230X1401646X

Structure of glutathione S-transferase 1 from the major human hookworm parasite Necator americanus (Na-GST-1) in complex with glutathione

Oluwatoyin A Asojo a,*, Christopher Ceccarelli a
PMCID: PMC4157412  PMID: 25195885

The structure of Na-GST-1 in complex with GST is reported.

Keywords: glutathione S-transferase, Necator americanus

Abstract

Glutathione S-transferase 1 from Necator americanus (Na-GST-1) is a vaccine candidate for hookworm infection that has a high affinity for heme and metal porphyrins. As part of attempts to clarify the mechanism of heme detoxification by hookworm GSTs, co-crystallization and soaking studies of Na-GST-1 with the heme-like molecules protoporphyrin IX disodium salt, hematin and zinc protoporphyrin were undertaken. While these studies did not yield the structure of the complex of Na-GST-1 with any of these molecules, co-crystallization experiments resulted in the first structures of the complex of Na-GST-1 with the substrate glutathione. The structures of the complex of Na-GST-1 with glutathione were solved from pathological crystalline aggregates comprising more than one crystal form. These first structures of the complex of Na-GST-1 with the substrate glutathione were solved by molecular replacement from data collected with a sealed-tube home source using the previously reported apo structure as the search model.

1. Introduction  

Human hookworm infection is a neglected tropical disease (NTD) that remains a major cause of anemia, malnutrition, generational poverty and underdevelopment for about one sixth of the world’s population (Hotez, 2008, 2009, 2010; Musgrove & Hotez, 2009; Brooker et al., 2008). Hookworm infection leads to lifelong health problems including neonatal prematurity, low birth weight and stunted physical and intellectual development in childhood (Musgrove & Hotez, 2009; Hotez, 2009; Brooker et al., 2008). Current deworming and sanitation programs have not effectively controlled hookworm infection because of the high rates of reinfection following drug treatment, emerging drug resistance and the inadequate coverage of global treatment (Bundy et al., 1995; Albonico et al., 1995, 2003; Knopp et al., 2012). As part of ongoing efforts to control hookworm infection, recombinant multivalent vaccines for hookworm infection are being investigated (Zhan et al., 2005). Adult-stage vaccine antigens include the cytosolic glutathione S-transferases (GSTs).

In addition to having antigenic properties, hookworm GSTs have been shown to have a high affinity for heme and metal porphyrins. This is considered to be an adaptation related to the blood-feeding activity of hookworms. Hookworm GSTs belong to a superfamily of isoenzymes that catalyze the detoxification of various compounds and protect against peroxidative damage (Armstrong, 1991). GSTs function as homodimers that inactivate and extrude electrophilic substrates by the nucleophilic addition of reduced glutathione (Ketterer, 1988; Ketterer et al., 1988). GSTs are the major detoxification system of hookworms, which lack cytochrome P-450 dependent enzymes (Brophy & Barrett, 1990; Precious & Barrett, 1989a ,b ). We previously solved the structures of the three GSTs from Necator americanus (Asojo et al., 2007; Kelleher et al., 2013). In order to understand the mechanism of heme detoxification by hookworm GSTs, we initiated co-crystallization and soaking studies with heme-like molecules, porphyrin and hematin. While our studies did not yield the structure of the complex of Na-GST-1 with any of these molecules, co-crystallization experiments resulted in the first structures of the complex of Na-GST-1 with the substrate glutathione.

2. Materials and methods  

2.1. Crystallization experiments  

The recombinant expression and purification of Na-GST-1 were as reported previously (Zhan et al., 2010). Crystals were grown as described previously (Asojo et al., 2007). Briefly, the protein was concentrated to 15 mg ml−1 in phosphate-buffered saline (PBS) or Tris–HCl pH 7.4 and crystals were grown at 298 K by vapor diffusion in sitting drops. Drops were prepared by mixing 3 µl protein solution with 1.5 µl reservoir solution consisting of 0.1 M sodium acetate pH 4.6, 30% PEG 400, from which crystals were obtained within two weeks. For soaking experiments, potential ligands were dissolved in the reservoir solution at a final concentration of at least 100 µM. Crystals were transferred into the soaking solution and incubated for a week. The compounds screened were protoporphyrin IX disodium salt, hematin and zinc protoporphyrin (Sigma–Aldrich). Soaking studies resulted in either a complete loss of diffraction or in apo structures of Na-GST-1 at a significantly lower resolution than those previously reported. The soaked crystals belonged to a different space group than that reported earlier (Asojo et al., 2007) and an example is described in the Supporting Information1. Consequently, all structural analyses were performed on co-crystals.

The best diffracting crystals were obtained from co-crystallization experiments with protoporphyrin IX disodium salt in sitting drops by mixing 3 µl protein solution with 1.5 µl reservoir solution consisting of 0.1 M sodium acetate pH 4.6, 40% PEG 400. The protein solution was 15 mg ml−1 Na-GST-1 in 50 mM Tris–HCl pH 7.4, which was incubated with 100 µM protoporphyrin IX disodium salt for one week at 277 K. Within a week, what appeared to be inseparable stacked crystalline aggregates of at least two crystals were produced; the sample selected for data collection appeared to be two crystals with approximate dimensions of 0.035 × 0.21 × 0.25 and 0.035 × 0.18 × 0.46 mm.

2.2. Data collection  

Data-collection experiments on the crystalline aggregates were carried out at 100 K using an Agilent SuperNova diffractometer equipped with a four-circle kappa platform, a 135 mm diagonal Atlas CCD detector and a high-brilliance sealed-tube (Cu) X-ray micro-source, with crystal-to-detector distances and exposure times that were optimized and determined using the CrysAlisPro strategy (v.1.171.36.28; Agilent Technology, Oxford, England). Data were collected to ensure spot separation using four scan runs at a 115 mm crystal-to-detector distance with 0.5° frame width and exposure times of 40 s per frame. The four scan runs were collected at different kappa values, which were selected to ensure 100% completeness in the triclinic space group (see below). A total of 618 frames were collected over a total elapsed experiment time of 14 h 3 min. The longer than expected data-collection time was because the data collection included frame correlation, background correction and overflow re-measurements.

3. Results and discussion  

3.1. Data processing  

Co-crystallization with protoporphyrin IX disodium salt resulted in crystalline aggregates that appeared to be distinct units, which always grew stacked on top of each other. The diffraction images suggest that there are reflections from multiple crystal forms in the crystal aggregate, and indexing in one lattice does not capture a significant subset of the reflections (Fig. 1). Three of these crystal forms account for two-thirds of all of the diffraction spots and could be indexed, whereas 32.4% of all of the diffraction spots could not be indexed and were rejected. The crystal forms were identified and data for each form were processed separately using the CrysAlisPro software package (Agilent Technologies, Oxford, England). All data were integrated using CrysAlisPro, which automatically processed and deconvoluted overlapping spots during integration. The deconvoluted reflections were not rejected.

Figure 1.

Figure 1

Sample diffraction image from the crystal aggregates. The diffraction image reveals reflections that belong to more than one crystal form. Predictions for the triclinic space group are superposed on the image.

Two of these crystal forms were triclinic, while the third belonged to the monoclinic space group C2. Additionally, the major crystal forms appear to be approximately aligned along their c axes. Crystal form 1 has unit-cell parameters a = 45.2, b = 47.8, c = 103.1 Å, α = 80.5, β = 78.7, γ = 62.0°. This crystal form comprised 39.1% of the total diffraction reflections (19.8% of the separated reflections and 19.4% of the overlapped reflections). The R merge for this crystal form was 7%. Crystal form 2 is also triclinic and has unit-cell parameters a = 45.0, b = 47.9, c = 104.9 Å, α = 80.2, β = 78.3, γ = 61.8°. Crystal form 2 comprised of 21% of the total diffraction reflections (6.3% of the separated reflections and 14.7% of the overlapped reflections). Although the unit cell of crystal form 2 was similar to that of crystal form 1, the R merge for crystal form 2 is 21%, which makes it unsuitable for structure determination. The third crystal form identified from the crystalline aggregate is the monoclinic crystal form 3, which has unit-cell parameters a = 84.6, b = 45.2, c = 113.8 Å, β = 112.1°. Crystal form 3 accounted for 34.9% of the total diffraction reflection spots (16.9% of the separated reflections and 18.0% of the overlapped reflections) and has an R merge of 7%. The redundancy of the monoclinic form is lower than expected for 309° of data because while the data collection was optimized to maximize completeness for one of the triclinic crystal forms, it was not necessarily oriented for the other components of the crystalline aggregate. Although the reduced cells for the triclinic and monoclinic forms are similar, attempts at indexing the triclinic form in monoclinic diffraction symmetry resulted in an R merge of 24% with unit-cell parameters a = 84.5, b = 45.2, 106.3 Å, α = 90, β = 108.5, γ = 90°. The intensity statistics for crystal forms 1 and 3 are shown in Table 1.

Table 1. Intensity statistics.

(a).

Monoclinic crystal form.

  Reflections            
Resolution (Å) Measured Theory Unique§ Completeness (%) Multiplicity I I/σ(I)〉 R int †† R σ ‡‡
∞–5.65 3677 1217 1076 88.4 3.4 2588.40 20.47 0.087 0.040
5.75–4.58 3313 1150 1076 93.6 3.1 3430.31 19.17 0.082 0.046
4.58–4.00 3070 1126 1076 95.6 2.9 4754.90 19.91 0.088 0.045
4.00–3.65 2793 1110 1076 96.9 2.6 4102.25 15.89 0.090 0.057
3.65–3.39 2614 1113 1076 96.7 2.4 3490.59 12.67 0.091 0.068
3.39–3.19 2630 1094 1076 98.4 2.4 2541.32 10.06 0.098 0.087
3.19–3.04 2612 1093 1076 98.4 2.4 2026.58 8.37 0.103 0.105
3.04–2.91 2443 1091 1076 98.6 2.3 1533.70 6.81 0.112 0.131
2.91–2.80 2341 1095 1076 98.3 2.2 1273.59 5.82 0.112 0.150
2.80–2.70 2215 1116 1083 97.0 2.0 1067.40 5.00 0.124 0.174
∞–2.70 27708 11205 10767 96.1 2.6 2783.72 13.25 0.093 0.072
(b).

Triclinic crystal form.

  Reflections            
Resolution (Å) Measured Theory Unique§ Completeness (%) Multiplicity I I/σ(I)〉 R int †† R σ ‡‡
∞–5.65 3808 2230 1737 77.9 2.2 2778.04 17.37 0.063 0.048
5.65–4.47 3502 2262 1737 76.8 2.0 3719.43 16.33 0.065 0.050
4.47–3.93 3167 2167 1737 80.2 1.8 4730.81 16.07 0.070 0.052
3.93–3.58 2783 2146 1737 80.9 1.6 4188.94 12.55 0.072 0.064
3.58–3.34 2521 2053 1737 84.6 1.5 3317.15 9.65 0.073 0.080
3.34–3.16 2364 1869 1737 92.9 1.4 2422.36 7.39 0.084 0.102
3.16–3.02 2264 1870 1737 92.9 1.3 1974.68 6.22 0.087 0.118
3.02–2.90 2210 1911 1737 90.9 1.3 1534.73 5.16 0.098 0.148
2.90–2.79 2136 1940 1737 89.5 1.2 1281.86 4.43 0.109 0.162
2.79–2.70 2119 2038 1745 85.6 1.2 1071.18 3.85 0.125 0.185
∞–2.70 26874 20488 17378 84.8 1.5 2872.81 10.94 0.072 0.071

Total number of observed reflections.

Total number of possible unique reflections.

§

Number of measured unique reflections.

Multiplicity = measured/unique.

††

R int = Inline graphic Inline graphic.

‡‡

R σ = Inline graphic Inline graphic.

3.2. Structure determination and refinement  

As previously reported, the expressed protein has 206 amino-acid residues (Asojo et al., 2007). The structures of both crystal forms were solved by molecular replacement with Phaser (McCoy et al., 2005; Storoni et al., 2004). The molecular-replacement search model was a monomer of Na-GST-1 (PDB entry 2on7) stripped of all ligands and water molecules (Asojo et al., 2007). Molecular replacement was followed by iterative cycles of manual model building with Coot (Emsley et al., 2010) and structure refinement with REFMAC5 (Murshudov et al., 2011) within the CCP4 package (Winn et al., 2011). The refined coordinates were subjected to PDB-REDO (Joosten, Salzemann et al., 2009; Joosten, Womack et al., 2009; Joosten et al., 2012) to optimize the model and this was followed by several additional cycles of manual building to fix any poorly fitting regions that were introduced during PDB-REDO. The data for each crystal form are of sufficient quality to yield clear and unambiguous crystal structure solutions. The resulting structures did not have protoporphyrin IX ligand bound; instead, both crystal forms are complexes with glutathione.

All main-chain atoms have visible electron-density maps in the triclinic structure except for the N-terminal residue in two chains, while some of the side chains are disordered. In the monoclinic structure the loop connecting residues Gly111 through Asp116 is disordered as well as the N-terminal residue in one chain. Overall, the triclinic structure is of better quality than the monoclinic structure, as reported in Table 2. The refinement statistics are consistent with the low resolution of the data sets as well as the pathology of the crystalline aggregates used for data collection. Despite this, there is good agreement of the refined models with the electron-density maps (Fig. 3). While the monoclinic crystal form has a dimer in the asymmetric unit, the triclinic crystal has two dimers in the asymmetric unit (Fig. 2). After taking into account the unit-cell translations as well as symmetry operators, a dimer of dimers can be generated from symmetry mates of the monoclinic crystal form that can be superposed with the triclinic crystal form. When both dimers of dimers are compared, it appears that the greatest difference is in the loop connecting Gly111 through Asp116, which is partly disordered, perhaps owing to conformational flexibility (Fig. 2 c). We previously reported multiple conformations of this loop in our structures of Na-GST-1 and Na-GST-2 (Asojo et al., 2007).

Table 2. Crystallographic data-collection and refinement statistics.

Values in parentheses are for the highest resolution shell.

Data set Monoclinic C2 Triclinic P1
PDB code 4ofn 4ofm
Unit-cell parameters
a, b, c (Å) 84.55, 45.2, 113.76 45.20, 47.84, 103.12
 α, β, γ (°) 90, 112.11, 90 80.54, 78.70, 61.99
Resolution (Å) 50–2.7 (2.8–2.7) 50–2.7 (2.8–2.7)
R merge (%) 7.1 (17.4) 7.2 (18.5)
No. of measured reflections 27708 (2119) 27708 (2119)
No. of unique reflections 10767 (1083) 17378 (1745)
Completeness (%) 96.1 (97.0) 84.8 (85.6)
Multiplicity 2.6 (2.0) 1.5 (1.2)
I/σ(I)〉 13.2 (5.0) 10.9 (3.8)
Refinement statistics
 Resolution (Å) 50–2.7 (2.8–2.7) 50–2.7 (2.8–2.7)
R cryst (%) 29.2 (32.1) 22.1 (28.5)
R free § (%) 33.0 (35.2) 26.7 (35.4)
 No. of atoms in model
  Protein 3340 6728
  Water 25 120
  GSH 40 60
 Mean B factor (Å2) 10.7 13.5
 R.m.s. deviation from ideal
  Bond lengths (Å) 0.006 0.012
  Bond angles (°) 0.971 1.608
  Chiral (Å3) 0.055 0.110
 Ramanchandran plot (%)
  Favored regions 95.1 96.1
  Allowed regions 4.4 3.3
  Outlier regions 0.5 0.6

R merge = Inline graphic Inline graphic, where I i(hkl) and 〈I(hkl)〉 are the intensity of measurement i and the mean intensity of the reflection with indices hkl, respectively.

R cryst =Inline graphic Inline graphic, where F obs are observed and F calc are calculated structure-factor amplitudes.

§

The R free set uses a randomly chosen 5% of the reflections.

Figure 2.

Figure 2

Asymmetric unit of the monoclinic and triclinic crystal forms. Cartoon diagrams are shown of the crystallographic asymmetric unit of the (a) monoclinic and (b) triclinic crystal forms. In the monoclinic dimer one monomer is colored green while the second is colored cyan. The monomers are colored green, cyan, yellow and magenta for the triclinic tetramer. Glutathione (GSH) is shown as sticks in all monomers. (c) The symmetry-generated dimer of dimers from the monoclinic form (shown in green and aquamarine) is superposed with the dimer of dimers from the triclinic form in gray and reveals that the major difference lies in the loop region indicated by a red arrow.

3.3. Glutathione binding and the active site  

Although no glutathione (GSH) was added to the crystallization mixture, unambiguous density for a glutathione molecule was observed in the GSH-binding site (G-site) of Na-GST-1 (Fig. 3). Surprisingly, glutathione binding of Na-GST-1 was only observed in the structures obtained from co-crystals and not those from the soaks or from native crystals (Asojo et al., 2007). The native crystals of the other N. americanus GSTs, Na-GST-2 (Asojo et al., 2007) and Na-GST-3 (Kelleher et al., 2013), had glutathione bound but no exogenous glutathione was added to any of the proteins. It is possible that glutathione was usurped during the fermentation process for all three enzymes. Overall, both the monoclinic and triclinic structures are similar to the previously reported orthorhombic apo crystal form of Na-GST-1 (Asojo et al., 2007). When the main chains of the biological dimers of the structures are superposed with each of the previously reported Na-GST-1 dimers, the r.m.s.d. is approximately 0.6 Å. The largest differences between all of the structures are in loop regions as well as in the active sites to accommodate glutathione binding. The ability to bind glutathione is prevented by Gln50 in the apo Na-GST-1 structure (Asojo et al., 2007). However, in the monoclinic and triclinic structures Gln50 adopts an alternative conformation which allows glutathione binding (Fig. 3). The interactions of the G-site residues with glutathione in Na-GST-1 are similar to those observed and reported in Na-GST-2 (Asojo et al., 2007) and Na-GST-3 (Kelleher et al., 2013). This is as expected since the residues forming the G-site are highly conserved in the three proteins (Kelleher et al., 2013).

Figure 3.

Figure 3

Glutathione binding. Refined model of GSH placed into F oF c maps calculated from molecular-replacement phases at the 2.5σ contour level for (a) one of the monomers of the monoclinic structure and (b) one of the monomers of the triclinic structure with electron-density maps for bound GSH in blue. The fit of the refined model in the REFMAC5-generated 2F oF c maps calculated from the refined model in gray contoured at 1σ is shown for one of the monomers of (c) the monoclinic and (d) the triclinic structures. (e) Superposed G-site residues of structures of Na-GST-1 in complex with GSH (green) and without bound GSH (gray) reveal the conformational flexibility of Asn50 that occludes GSH binding; GSH from the former structure is colored magenta.

4. Concluding remarks  

The active form of Na-GST-1 is a homodimer and all homodimers from the reported crystal structures are very similar. The pairwise superposition r.m.s. deviation for all main-chain atoms does not exceed 0.6 Å. Attempts at soaking and co-crystallizing Na-GST-1 with several ligands did not result in the binding of any of these ligands. Co-crystallization studies instead yielded the first structures of Na-GST-1 in complex with the substrate glutathione. We have previously reported that Na-GST-1 is an efficient detoxifier of many molecules (Goud et al., 2012; Asojo et al., 2007), which may contribute to the inability of the tested ligands to stay bound to the enzyme. We noted significant structural similarity of the three N. americanus GSTs, Na-GST-1, Na-GST-2 and Na-GST-3. Since the in vitro enzymatic activity of Na-GST-2 and Na-GST-3 are lower than that of Na-GST-1 (Asojo et al., 2007) these may be more suitable enzymes for structural studies of heme binding in hookworm GSTs. Alternative approaches may include generating ligands that will covalently bind to the active site.

Supplementary Material

PDB reference: Na-GST-1, 4ofm

PDB reference: 4ofn

Supporting Information.. DOI: 10.1107/S2053230X1401646X/sx5114sup1.pdf

f-70-01162-sup1.pdf (428.8KB, pdf)

Acknowledgments

This project was supported by startup funds provided by the National School of Tropical Medicine at the Baylor College of Medicine (OAA).

Footnotes

1

Supporting information has been deposited in the IUCr electronic archive (Reference: SX5114).

References

  1. Albonico, M., Bickle, Q., Ramsan, M., Montresor, A., Savioli, L. & Taylor, M. (2003). Bull. World Health Organ. 81, 343–352. [PMC free article] [PubMed]
  2. Albonico, M., Smith, P. G., Ercole, E., Hall, A., Chwaya, H. M., Alawi, K. S. & Savioli, L. (1995). Trans. R. Soc. Trop. Med. Hyg. 89, 538–541. [DOI] [PubMed]
  3. Armstrong, R. N. (1991). Chem. Res. Toxicol. 4, 131–140. [DOI] [PubMed]
  4. Asojo, O. A., Homma, K., Sedlacek, M., Ngamelue, M., Goud, G. N., Zhan, B., Deumic, V., Asojo, O. & Hotez, P. J. (2007). BMC Struct. Biol. 7, 42. [DOI] [PMC free article] [PubMed]
  5. Brooker, S., Hotez, P. J. & Bundy, D. A. (2008). PLoS Negl. Trop. Dis. 2, e291. [DOI] [PMC free article] [PubMed]
  6. Brophy, P. M. & Barrett, J. (1990). Parasitology, 100, 345–349. [DOI] [PubMed]
  7. Bundy, D. A., Chan, M. S. & Savioli, L. (1995). Trans. R. Soc. Trop. Med. Hyg. 89, 521–522. [DOI] [PubMed]
  8. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. (2010). Acta Cryst. D66, 486–501. [DOI] [PMC free article] [PubMed]
  9. Goud, G. N., Deumic, V., Gupta, R., Brelsford, J., Zhan, B., Gillespie, P., Plieskatt, J. L., Tsao, E. I., Hotez, P. J. & Bottazzi, M. E. (2012). Protein Expr. Purif. 83, 145–151. [DOI] [PubMed]
  10. Hotez, P. (2008). Ann. N. Y. Acad. Sci. 1136, 38–44. [DOI] [PubMed]
  11. Hotez, P. J. (2009). PLoS Negl. Trop. Dis. 3, e539. [DOI] [PMC free article] [PubMed]
  12. Hotez, P. J. (2010). Sci. Am. 302, 96. [DOI] [PubMed]
  13. Joosten, R. P., Joosten, K., Murshudov, G. N. & Perrakis, A. (2012). Acta Cryst. D68, 484–496. [DOI] [PMC free article] [PubMed]
  14. Joosten, R. P., Salzemann, J. et al. (2009). J. Appl. Cryst. 42, 376–384. [DOI] [PMC free article] [PubMed]
  15. Joosten, R. P., Womack, T., Vriend, G. & Bricogne, G. (2009). Acta Cryst. D65, 176–185. [DOI] [PMC free article] [PubMed]
  16. Kelleher, A., Zhan, B. & Asojo, O. A. (2013). Acta Cryst. F69, 839–843. [DOI] [PMC free article] [PubMed]
  17. Ketterer, B. (1988). Mutat. Res. 202, 343–361. [DOI] [PubMed]
  18. Ketterer, B., Meyer, D. J. & Tan, K. H. (1988). Basic Life Sci. 49, 669–674. [DOI] [PubMed]
  19. Knopp, S., Steinmann, P., Keiser, J. & Utzinger, J. (2012). Infect. Dis. Clin. North Am. 26, 341–358. [DOI] [PubMed]
  20. McCoy, A. J., Grosse-Kunstleve, R. W., Storoni, L. C. & Read, R. J. (2005). Acta Cryst. D61, 458–464. [DOI] [PubMed]
  21. Murshudov, G. N., Skubák, P., Lebedev, A. A., Pannu, N. S., Steiner, R. A., Nicholls, R. A., Winn, M. D., Long, F. & Vagin, A. A. (2011). Acta Cryst. D67, 355–367. [DOI] [PMC free article] [PubMed]
  22. Musgrove, P. & Hotez, P. J. (2009). Health Aff. 28, 1691–1706. [DOI] [PubMed]
  23. Precious, W. Y. & Barrett, J. (1989a). Biochim. Biophys. Acta, 992, 215–222. [DOI] [PubMed]
  24. Precious, W. Y. & Barrett, J. (1989b). Parasitol. Today, 5, 156–160. [DOI] [PubMed]
  25. Storoni, L. C., McCoy, A. J. & Read, R. J. (2004). Acta Cryst. D60, 432–438. [DOI] [PubMed]
  26. Winn, M. D. et al. (2011). Acta Cryst. D67, 235–242.
  27. Zhan, B. et al. (2005). Infect. Immun. 73, 6903–6911. [DOI] [PMC free article] [PubMed]
  28. Zhan, B. et al. (2010). Infect. Immun. 78, 1552–1563. [DOI] [PMC free article] [PubMed]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

PDB reference: Na-GST-1, 4ofm

PDB reference: 4ofn

Supporting Information.. DOI: 10.1107/S2053230X1401646X/sx5114sup1.pdf

f-70-01162-sup1.pdf (428.8KB, pdf)

Articles from Acta Crystallographica. Section F, Structural Biology Communications are provided here courtesy of International Union of Crystallography

RESOURCES